Upcoming Event

PRESS

All information about the IZB – the press area

+++ Thermosome Initiates Final Dose Level in Phase I Trial of Lead compound THE001 +++

+++ SciRhom announces first dosing in First-in-Man trial for lead program SR-878 +++

+++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA +++

+++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. +++

+++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 +++

+++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 +++

+++ Tubulis secures significant EUR 128 million Series B2 financing +++

+++ Novel small molecule drugs of the future targeting the CNS +++

+++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) +++

+++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level +++

+++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis +++

+++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments +++

+++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq +++

+++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million +++

+++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 +++

+++ Renowned Peutinger-Collegium visits the IZB +++

+++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 +++

+++ GoingPublic celebrates a quarter century of biotech +++

+++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency +++

+++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell +++

+++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology +++

+++ High-Profile Clinical Advisory Board for Thermosome +++

+++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker +++

+++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation +++

+++ adivo becomes part of the world’s leading animal health company Zoetis +++

+++ The Munich Bavaria Student Union visits the IZB +++

+++ Bind-X secures €10 million in financing as part of its Series B financing round +++

+++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research +++

+++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program +++

+++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub +++

+++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy +++

+++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease +++

+++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO +++

+++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB +++

+++ Japanese delegation visits the IZB +++

+++ Bavarian biotechnology maintains its position in the crisis and continues to grow +++

+++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board +++

+++ Official handover ceremony at the Annual Meeting of the Max Planck Society +++

+++ Secarna appoints new Chief Business Officer +++

+++ Bicoll showcases at BIO International Convention +++

+++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma +++

+++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry +++

+++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies +++

+++ Biotech report by vfa: Biopharmaceuticals successfully gain market share +++

+++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa +++

+++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics +++

+++ Non-nutritive sweeteners may affect the human immune system +++

+++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” +++

+++ Invitris receives 250,000 EUR to complete spin-out from TUM +++

+++ Eisbach starts phase I clinical trial with COVID-19 antiviral +++

+++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park +++

+++ Specific packaging of DNA affects cell division +++

+++ Tubulis Enters Strategic Partnership with BMS +++

+++ Insempra launches its first functional component for consumer goods +++

+++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman +++

+++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease +++

+++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership +++

+++ adivo expands into new headquarters as first clinical study begins +++

+++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial +++

+++ Construction of the “New Hauner” at the Grosshadern Campus has started +++

+++ Insempra names new Chief Operating Officer +++

+++ Training events for project managers and biological safety officers +++

+++ The zebrafish brain as a map +++

+++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure +++

+++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris +++

+++ When life begins too early +++

+++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease +++

+++ Expansion of the Munich “science line” has started +++

+++ Enno Spillner to join Formycon as CFO +++